We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Study Identifies Gene Variants Linked to AD in African Americans

By LabMedica International staff writers
Posted on 08 Mar 2017
In what may have been the first comprehensive screening of rare coding variants in an African American population, researchers identified several rare gene variants linked to the development of early onset Alzheimer's disease (AD).

Investigators at the Mayo Clinic searched for mutations in three genes, APP, PSEN1, and PSEN2, known to contribute to early-onset Alzheimer’s disease. More...
Presenilin-1 and -2 (PS-1, PS-2) are presenilin proteins that in humans are encoded by the PSEN1 and PSEN2 genes. Presenilin-1 and -2 are two of the four core proteins in the gamma secretase complex, which is considered to play an important role in generation of amyloid beta (A-beta) from amyloid precursor protein (APP). Accumulation of amyloid beta is associated with the onset of Alzheimer's disease. APP (Amyloid precursor protein) is an integral membrane protein expressed in many tissues and concentrated in the synapses of neurons. Its primary function is not known, though it has been implicated as a regulator of synapse formation, neural plasticity, and iron export. APP is best known as the precursor molecule whose proteolysis generates beta amyloid (A-beta), a polypeptide containing 37 to 49 amino acid residues, whose amyloid fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients.

The investigators conducted a comprehensive screening of rare coding variants in an African American cohort to identify novel pathogenic mutations within the early-onset Alzheimer’s disease (EOAD) genes (APP, PSEN1, and PSEN2) in this understudied population. Whole-exome sequencing of 238 African American subjects identified six rare missense variants within the EOAD genes, which were observed in AD cases but never among controls.

These variants were analyzed in an independent cohort of 300 African American subjects, in whom the PSEN1/PSEN2 variants were again not observed, indicating that these novel rare variants may contribute to AD risk in this population.

“Currently, at least five million Americans are affected by Alzheimer’s disease, and the rate of this devastating dementia is expected to rise dramatically in the coming decades,” said contributing author Dr. Minerva Carrasquillo, a neuorgeneticist at the Mayo Clinic. “By uncovering genetic factors that modify the risk of Alzheimer's disease, there is the potential to identify druggable gene targets and genetic variants that could be used for early disease detection and prevention.”

“PSEN1 variants had been found before in African-Americans with the disease, but this discovery of a likely pathogenic PSEN2 gene variant is new in this population,” said Dr. Carrasquillo. “And as far as we know, it has not been found in other populations with late onset Alzheimer’s disease. This study opens the door to further analysis of this gene variant ─ both in African-Americans with Alzheimer’s and in other populations.”

The study was published in the February 2017 issue of the Journal of Alzheimer’s Disease.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.